Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks
The Cochrane Database of Systematic ReviewsPublished 25 October 1999
Oscar Benavente, Robert G. Hart, Peter J. Koudstaal, Andreas Laupacis, Ruth McBride
Citations29
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Considering all randomized data, aspirin modestly reduces stroke and major vascular events in nonvalvular AF, and reductions in these events by aspirin were consistently smaller and marginally statistically significant.
Abstract
Considering all randomized data, aspirin modestly (by about 20%) reduces stroke and major vascular events in nonvalvular AF. For primary prevention among AF patients with an average stroke rate of 4.5%/year, about 10 strokes would be prevented yearly for every 1000 given aspirin.
Keywords
Medicine
StrokeAtrial fibrillation as an independent risk factor for stroke: the Framingham Study.
7,462 Citations1991Philip A. Wolf, Robert D. Abbott +1 more
The data suggest that the elderly are particularly vulnerable to stroke when atrial fibrillation is present, and the effects of hypertension, coronary heart disease, and cardiac failure on the risk of stroke became progressively weaker with increasing age.
The LancetPLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION
1,826 Citations1989Palle Petersen, J Godtfredsen +3 more
The incidence of thromboembolic complications and vascular mortality were significantly lower in the warfarin group than in the aspirin and placebo groups, which did not differ significantly.
The LancetSecondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
1,744 Citations1993EAFT Study Group
It is concluded that anticoagulation is effective in reducing the risk of recurrent vascular events in NRAF patients with a recent TIA or minor ischaemic stroke; it prevents 40 vascular events each year for every 1000 treated patients.
CirculationStroke Prevention in Atrial Fibrillation Study. Final results.
1,712 Citations1991
Aspirin and warfarin are both effective in reducing ischemic stroke and systemic embolism in patients with atrial fibrillation and patients with nonrheumatic atrialfibrillation who can safely take either aspirin or warfarIn should receive prophylactic antithrombotic therapy to reduce the risk of stroke.
Journal of the Neurological SciencesEuropean Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
1,564 Citations1996Hans‐Christoph Diener, Luı́s Cunha +4 more
Low-dose ASA does not eliminate the propensity for induced bleeding and the combination of ASA and dipyridamole, in a modified-release form, at a dose of 200 mg twice daily have each been shown to be equally effective for the secondary prevention of ischemic stroke and TIA.
Journal of Neurology Neurosurgery & PsychiatryThe United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.
1,212 Citations1991Barbara Farrell, Jon Godwin +2 more
The odds of suffering a major stroke, myocardial infarction or vascular death were 15% less in the combined aspirin groups compared with the placebo group which is compatible with the continuing overview of all the similar trials of antiplatelet drugs.
New England Journal of MedicineThe Natural History of Lone Atrial Fibrillation
932 Citations1987Stephen L. Kopecky, Bernard J. Gersh +5 more
It is concluded that lone atrial fibrillation in patients under the age of 60 at diagnosis is associated with a very low risk of stroke, and routine anticoagulation may not be warranted.
StrokeFactors Associated With Ischemic Stroke During Aspirin Therapy in Atrial Fibrillation
535 Citations1999Robert G. Hart, Lesly A. Pearce +3 more
Patients with AF who have high and low rates of stroke during treatment with aspirin can be identified and validation of the risk stratification scheme is necessary before it can be applied with confidence to clinical management.
Annals of Internal MedicinePredictors of Thromboembolism in Atrial Fibrillation: I. Clinical Features of Patients at Risk
478 Citations1992The Stroke Prevention in Atrial Fibrillation Investigators
Patients with atrial fibrillation at high risk and low risk for thromboembolism can be identified by readily available clinical variables by multivariate analysis.
Archives of Internal MedicinePrevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications
361 Citations1995W. M. Feinberg
StrokeIndobufen Versus Warfarin in the Secondary Prevention of Major Vascular Events in Nonrheumatic Atrial Fibrillation
200 Citations1997C Morocutti, G Amabile +9 more
Indobufen, a reversible inhibitor of platelet cyclooxygenase, with warfarin may help the medical community in devising appropriate antithrombotic strategies for NRAF patients for whom oral anticoagulants are contraindicated or do not represent a feasible approach to treatment.
Journal of Stroke and Cerebrovascular DiseasesRisk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The stroke prevention in atrial fibrillation study
138 Citations1995
Exploratory analyses suggest that many AF patients may have a relatively low thromboembolic rate when given aspirin, but the findings must be independently confirmed before being applied to clinical management.